MONIQUE ANN SPILLMAN, MD PhD
CONTACT INFORMATION
OB/GYN, B198-4
Academic Office 1
12631 East 17th Avenue, Room 4411
P.O. Box 6511
Aurora, CO 80045
monique.spillman@ucdenver.edu
Clinical Office: (303) 724-2066
Cell: (720) 253-3834
FAX: (303) 724-2053
Pager: (303) 266-1939
EDUCATION AND EMPLOYMENT
University of Colorado at Denver
Assistant Professor, Department of Obstetrics and Gynecology, July 2006
Assistant Professor, Endocrinology, Metabolism and Diabetes, October, 2008
Women’s Reproductive Health Research Scholar
Cancer Center Full Member, Program in Endocrine Related Malignancies
Duke University Medical Center
Gynecologic Oncology Fellowship, 2003- June, 2006
Brigham and Women’s Hospital/Massachusetts General Hospital Integrated Residency
Obstetrics and Gynecology Residency, 1999- 2003.
The University of Texas Southwestern Medical School and Graduate School
M.D. and Ph.D. Degrees awarded June, 1999.
The University of Texas at Austin
Bachelor of Arts in biochemistry, high honors, May, 1989.
LICENSURE AND CERTIFICATION
Colorado Physician’s License, 44646; Issued 5/10/06, renewed 2009
North Carolina Full and Unrestricted Medical License, 2003-00710; Issued 06/03, renewed 2009
Texas Medical License, N2304, Issued 2/09
DEA Certificate, Schedules 2, 3, 3N, 4, 5, expires 02/10
Diplomate, American Board of Obstetrics and Gynecology, January, 2008
Fellow, American College of Obstetricians and Gynecologists, January, 2009
Special Certification in Gynecologic Oncology, April, 2009
PEER-REVIEWED ARTICLES
1. Ali AA, Finlay JL, Gerald WL, Nisen P, Rosenfield NS, LaQuaglia MP, Spillman M,
O'Malley B, and Fraser R. Congenital mesoblastic nephroma with metastasis to the brain: a case
report. American Journal of Pediatric Hematology-Oncology, 16: 361-4, 1994.
2. Osborne-Lawrence S, Welcsh PL , Spillman M, Chandrasekharappa SC, Gallardo TD,
Lovett M, and Bowcock AM. Direct selection of expressed sequences within a 1Mb region
flanking BRCA1 on human chromosome 17q21. Genomics, 25: 248-255, 1995.
3. Abel KJ, Brody LC, Valdes JM, Erdos MR, McKinley DR, Castilla LH, Merajver SD, Couch
FJ, Friedman LS, Ostermeyer EA, Lynch ED, King M-C, Welcsh PL, Osborne-Lawrence S,
Spillman M, Bowcock AM, Collins FS, and Weber BL. Characterization of EZH1, a human
homolog of Drosophila Enhancer of zeste near BRCA1. Genomics , 37: 161-171, 1996.
4. Spillman MA, and Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately
elevated in human breast cancer cells in response to estrogen. Oncogene, 13:1639-1645, 1996.
5. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang M-C, Hwang L-Y,
Bowcock AM, and Baer R. Identification of a RING protein that interacts in vivo with the
BRCA1 gene product. Nature Genetics, 14: 430-440, 1996.
6. Thai TH, Du FH, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R,
Mathis JM, Miller DS, Trask BJ, Baer R, and Bowcock AM. Mutations in the BRCA1-associated
ring domain (BARD1) gene in primary breast, ovarian and uterine cancers. Human Molecular
Genetics, 7:195-202, 1998.
7. Tomlinson GE, Chen TT-L, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum
JL,Schneider NR, Wistuba II, Shay JW, Minna JD, and Gazdar AF. Characterization of a breast
cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Research, 58:32373242, 1998.
8. Morin K, Rakatansky H, Riddick FA Jr., Morse LJ, O’Bannon JM 3rd, Goldrich MS, Ray P,
Weiss M, Sade RM, Spillman, MA. Conflicts of interests in clinical trials. JAMA, 287(1): 78-84,
2002.
9. Taub S, Morin K, Spillman MA, Sade RM, Riddick FA; Council on Ethical and Judicial
Affairs of the American Medical Association. Managing familial risk in genetic testing. Genet.
Test. 8 (3): 356-9, 2004.
10. Taub S, Morin K, Sade RM, Spillman, MA; Council on Ethical and Judicial Affairs of the
American Medical Association. Safeguards in the use of DNA databanks in genomic research.
Genet. Med. 6(6): 526-9, 2004.
11. Spillman MA, and Berchuck A. “Stretching the surface epithelium,” Journal of Society of
Gynecologic Investigation, 11(8):501-2, 2005.
Spillman,
3
12. Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR,
Murphy S, Berchuck A. Transforming growth factor β receptor I polyalanine repeat
polymorphism does not increase ovarian cancer risk. Gynecologic Oncology, 97:543-549,2005.
13. Murphy SK , Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks
JR and Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2
expression in epithelial ovarian cancer. Molecular Cancer Research, 4(4): 283-292, 2006.
14. Soper JT, Spillman MA, Sampson JH, Kirkpatrick JP, Wolf JK, Clarke-Pearson DL.
High-risk Gestational Trophoblastic Neoplasia with brain metastases: individualized
multidisciplinary therapy in the management of four patients. Gynecologic Oncology, 104: 691–
694, 2007.
15. Spillman MA and Sade, R. Clinical Trials of Xenotransplantation: Waiver of the Right to
Withdraw from a Clinical Trial Should Be Required. J Law Med Ethics, Summer;35(2):265-72,
2007.
16. Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace LA, Teaberry V, Marks JR,
Berchuck, A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
Gynecologic Oncology, 105(2):312-20, 2007.
17. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB and Jacobsen BM.
“Progesterone Receptor Action: Translating studies in breast cancer models to clinical insights,”
Advances in Experimental Medicine & Biology. 630:94-111, 2008.
18. Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM,
Horwitz KB. “Tissue Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and
Metastasis.” Submitted Cancer Research, 2010
MANUSCRIPTS IN PREPARATION
Spillman MA, Jackson T, Bradford A, Helfrich B, Korch C, Horwitz K, Jacobsen, B. “DNA Genotype
Authentication of Ovarian Cancer Cell Lines: Provenance versus Proof in the Womens’ Cancer Cell
Atlas.”
Embry J, Kelly MG, Post DM, and Spillman MA. “Chemotherapy Improves Survival in Large Cell
Neuroendocrine Carcinoma of the Cervix: A Case Report and Review of the Literature.”
Conageski C, Helfrich B, Conner A, Behbakht K, and Spillman M. “Anti-Proliferative Activity of cSRC Kinase Inhibitior Saracatinib Correlates with IGF1R and EGFR Expression in Ovarian Cancer Cell
Lines.”
Spillman,
4
BOOK CHAPTERS
Spillman MA, Berchuck A. Diagnosis and management of hereditary cancer. Glass' Office
Gynecology, 7th edition, (Curtis M, Overholt S, Hopkins MP eds.) Lippincott, Williams and
Wilkins, Philadelphia, 2010.
Spillman MA, Berchuck A. Diagnosis and management of hereditary cancer. Glass' Office
Gynecology, 6th edition, (Curtis M, Overholt S, Hopkins MP eds.) Lippincott, Williams and
Wilkins, Philadelphia, 2006.
Clarke-Pearson DL, Spillman MA, Lutman, CV, Lee PS. Preoperative Evaluation and
Postoperative Management. Clinical Gynecology, 1st edition, (Bieber E, Sanfilippo J, and
Horowitz I, eds.), Elsevier, Churchill Livingstone Title, 2006.
Lee PS, Spillman MA, Lutman CV, and Clarke-Pearson DL. Preoperative Evaluation. Berek and
Novak’s Gynecology, 14th edition (Berek, J, ed.) Lipincott, Williams, and Wilkins, 2006.
PRESENTATIONS AT NATIONAL/ INTERNATIONAL MEETINGS
“Reversal of Chemoresistance to Paclitaxel by reintroduction of microRNA-200c in
ovarian cancer cells,” AACR Annual Meeting, Washington DC, 2010.
“Estrogen Replacement Therapy Induces a Unique Gene Expression Pattern in Ovarian
Cancer,” Keystone Symposium Nuclear Receptors: Signaling, Gene Regulation, and Cancer,
Keystone, 2010.
“Anti-Proliferative Activity of c-SRC Kinase Inhibitor Saracatinib Correlates with IGF1R and
EGFR Expression in Ovarian Cancer Cell Lines,.” 41st Annual Meeting of the Society of Gynecologic
Oncologists, San Francisco, 2010.
“DNA Genotype Authentication of Ovarian Cancer Cell Lines: Provenance versus
Proof.” 40th Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, 2009.
“Estrogen Replacement Therapy Promotes Extraperitoneal Lymph Node Metastases in a
Mouse Xenograft Ovarian Cancer Model.” 40th Annual Meeting of the Society of Gynecologic
Oncologists, San Antonio, 2009.
“Estrogen alters tumor growth and metastatic pattern in a human ovarian cancer
xenograft model.” International Gynecologic Cancer Society, Bangkok, Thailand, 2008.
“Estrogen alters tumor growth and metastatic pattern in a human ovarian cancer
xenograft model.” American Association for Cancer Research Meeting, San Diego, 2008.
“Regulation of metastasis suppressor gene MKK4 in ovarian cancer,” 37th Annual
Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006.
“Relationship between polymorphisms in the progesterone and type I TGF-β receptors
Spillman,
5
and ovarian cancer risk,” presented at the 10th Biennial Meeting of the International Gynecologic
Cancer Society, Edinburgh, Scotland, 2004.
“Nuclear oncogene ETV4 is overexpressed in ovarian cancer,” presented at the 33rd
Annual Society of Gynecologic Oncologists Meeting, Miami, 2002.
“Estrogen upregulates ETV4 mRNA transcript levels,” presented at the 93rd Annual
American Association for Cancer Research Meeting, San Francisco, 2002.
“BRCA1 and BRCA2 mRNAs are coordinately elevated in breast cancer cells by
estrogen,” presented at the American Society of Human Genetics Meeting, San Francisco, 1996.
“The use of mRNA differential display to isolate genes altered in breast cancer
progression,” presented at the American Society of Human Genetics Meeting, San Francisco,
1996.
PUBLISHED ABSTRACTS
Spillman MA, Behbakht K, Kelly M, Davidson S. A Phase II Study of Fulvestrant
(Faslodex®) as a Maintenance Chemopreventative Agent in Advanced Serous Epithelial Ovarian
Cancer after Complete Response to Frontline Surgery and Chemotherapy, AACR/ASCO
Methods in Clinical Cancer Research Workshop, Vail, CO, August, 2009.
Spillman MA, Sartorius CA, Harrell JC, Manning NG, Jacobsen BM, Horwitz KB.
Estrogen alters tumor growth and metastatic pattern in a human ovarian cancer xenograft model.
Supplement, AACR Annual Meeting, 2008.
Spillman MA, Lacy J, Whitaker RS, Grace L, Teaberry V, Murphy SK, and Berchuck
A. Regulation of metastasis suppressor gene MKK4 in ovarian cancer. Gynecologic Oncology
Supplement 101: S170, 2006.
Spillman MA, Schildkraut JM, Calingaert B, Wenham RM, Marks JR, Spurdle AB,
Chenevix-Trench G, and Berchuck A. Relationship between polymorphisms in the progesterone
and type I TGF-β receptors and ovarian cancer risk. Supplement, International Journal of
Gynecologic Oncology.
Murphy SK, Spillman MA, Whitaker RS, Marks JM, and Berchuck A. Epigenetic
alterations and deregulated IGF2 expression in ovarian cancer. American Association of Cancer
Research, 95thAnnual meeting, Orlando, FLA, 2004.
Spillman MA, Du F, Zhao C, and Bowcock AM. The use of mRNA differential display
to isolate genes altered in breast cancer progression. American Journal of Human Genetics , 59
Supplement: A52, 1996.
Bowcock AM, and Spillman MA. BRCA1 and BRCA2 mRNAs are coordinately elevated
in breast cancer cells by estrogen. American Journal of Human Genetics, 59 Suppl: A35, 1996.
Spillman,
6
Spillman MA, and Bowcock AM. Estrogen stimulation of the BT-483 cell line results in
increased levels of BRCA1 and ETV4 mRNAs. American Journal of Human Genetics,
57 Supplement:A5, 1995.
Welcsh PL, Osborne-Lawrence SL, Spillman MA, Lovett M, and Bowcock AM.
Characterization of direct selected cDNAs from BRCA1 region of 17q21.American
Journal of Human Genetics, 55 Supplement: A274, 1994.
INVITED LECTURES
“Pelvic Masquerade: Genitourinary tuberculosis,” Grand Rounds, Cape Fear Valley
Medical Center, March, 2004.
“Bump Down There: A primer of vulvar dermatology,” Grand Rounds, Cape Fear Valley
Medical Center, November, 2004.
“Residents and Fellows: Needs, Knowledge and Attitudes,” North Carolina Leadership
College Select Presentation, North Carolina Medical Society Annual Meeting, 2004.
“Radiation Oncology – the basics,” OB/Gyn Resident Core Didactic Lecture, April, 2005.
“Pelvic Masquerade: Genitourinary tuberculosis,” Grand Rounds, WakeMed Medical
Center, July, 2005.
“Clinical trials of xenotransplantation: is a waiver of the right to withdraw required?”
Pitts Lectureship in Medical Ethics: Reflections on Emerging Technologies at the Centennial
of Organ Transplantation, Medical University of South Carolina, September, 2005.
“Ovarian and Cervical Cancer: The Quiet Ones,” invited lecture Friends of Nursing
Living Well Conference, February, 2006.
“A Stem-ulating Topic: Science, Policy and Ethics of Stem Cells,” Duke Department of
Obstetrics and Gynecology Grand Rounds, March, 2006.
“Human Papilloma Virus: Statistics and Science,” Colorado Obstetrics and Gynecology
Society, Garden of the Gods, September, 2006.
“Radical Radiation Oncology for Residents,” Gynecologic Oncology Minisymposium,
Department of Obstetrics and Gynecology, University of Colorado at Denver and Health
Sciences, November, 2006.
“Ovarian Cancer:
UCHSC, April, 2007.
A Steroid Regulated Disease?” Reproductive Sciences Seminar,
“Ovarian Cancer: A Steroid Regulated Disease?,” Hormone Related Malignancies &
Division of Endocrinology, Metabolism & Diabetes Research Seminar, UCHSC, April, 2007.
Spillman,
7
“Career Options after an MD/PhD” panelist at the 22nd annual National MD/PhD
Meeting, Keystone, 2007.
Plenary Session Discussant, “Cancer Stem Cell Gene Signature Identified from Ovarian
Tumor Side Populations,” Society of Gynecologic Oncologists, 39th Annual Meeting, 2008.
“Ethics of Genetic Testing in Gynecologic Oncology,” Society of Gynecologic Nurse
Oncologists, Denver, March, 2008.
“Research in Prevention and Early Detection Optimizes Gynecologic Cancer Care,”
Society of Gynecologic Oncologists Capitol Hill Briefing, Washington, DC, September, 2008.
“Ovarian Cancer: A Steroid Hormone Responsive Disease?” University of Texas
Southwestern Department of OB/Gyn Grand Rounds, June, 2009.
“What’s in Your Genes?:Genetic Testing in Gynecologic Oncology,” Department of
OB/Gyn Grand Rounds, University of Colorado Denver, August, 2009.
“What’s in Your Genes?: Genetic Testing in Gynecologic Oncology,” Grand Rounds,
Portsmouth Naval Hospital, Portsmouth, VA, September, 2009.
“Ovarian Cancer: Accessories Matter,” Ovarian Cancer Research Fund Super Luncheon,
Governor’s Mansion, Denver CO, September, 2009.
“Estrogen Replacement Therapy Induces a Unique Gene Expression Pattern in Ovarian
Cancer,” Hormone Related Malignancies Seminar, UCD, December, 2009.
“Health Care Reform: Policies that Affect Gynecologic Cancer Care,” plenary session,
Society of Gynecologic Oncologists 41st Annual Meeting, San Francisco, 2010.
TEACHING EXPERIENCES
Supervision and teaching of Duke OB/GYN residents and MSII students on the
gynecologic oncology service, Duke University Medical Center, 2004-2006.
Supervision and teaching of HMS III students in core clinical clerkship of OB/GYN;
Brigham and Women’s Hospital and Massachusetts General Hospital, 1999-2003.
Organization and teaching of minisymposium for CREOG review for University of Colorado
Health Sciences Center residency, 2007-present
Supervision and teaching of UCD OB/GYN residents and MSIII students on the
gynecologic oncology service, University of Colorado Denver, 2006-present.
Ovarian and Endometrial Cancer lectures, MSIII Core Course, UCD, 2009-present
Spillman,
8
UCD Graduate School Tumor and Cell Biology Course, lectures on cervical cancer and ovarian
cancer, 2007-present.
HONORS AND SCHOLARSHIPS
Faculty Teaching Award, Dpt OB/Gyn, UCHSC, 2007.
Fellows’ Research Prize, Dpt. of OB/GYN, Duke University Medical Center, 2006.
North Carolina Medical Society Foundation Leadership College Scholar, 2004.
Alpha Omega Alpha, 1999.
Dallas-Fort Worth Obstetrics and Gynecology Society Award, 1999.
Phi Beta Kappa, 1989.
National Merit Scholar, Dedman Scholarship, 1985-1989.
NIH Medical Scientist Training Program Fellowship, 1989-1992.
H. Ross Perot Foundation Fellowship for M.D./Ph.D. students, 1989-1999.
PROFESSIONAL ORGANIZATIONS AND ACTIVITIES
Society of Gynecologic Oncologists
Government Relations Committee
Chair, 2010-2012
Vice-Chair, 2008-2010
Member, 2005- present
Full member, 2009American College of Obstetricians and Gynecologists
Fellow, 2009-present
Junior Fellow, 1999- 2008
Committee on Ethics
Vice-Chair, 2010
Member, 2007-present.
AMA-CEJA liaison, 2000-2006
Alternate Delegate, ACOG Delegation to the AMA, Young Physician, 2006-present
American Association for Cancer Research
Full Member, 2007- present
Associate Member, 2001-2007
Women in Cancer Research Member (WICR)
International Gynecologic Cancer Society
Member, 2008-present
Spillman,
9
American Medical Association
Member, 1990-present
Council on Ethical and Judicial Affairs Resident/Fellow Representative, 2000-2006.
Council on Scientific Affairs Student Representative, 1993-1995.
Colorado Medical Society
Member, 2006-present
Denver County Medical Society
Member, 2006-present.
North Carolina Medical Society
Member, 2003 – 2006
Foundation Leadership College Scholar, 2004.
Massachusetts Medical Society
Member, 1999-2003
Out-of-state Member, 2003-present.
MMS-RPS Executive Council, 2000-2003
New England Delegation to the AMA 2000-2003
Texas Medical Association
Member in abstentia, 1999-2006.
Member in abstentia, Dallas County Medical Society, 1999-2006.
Member, Special Committee on Genetics, 1998.
Member, Special Committee on Physician Workforce Planning, 1996.
Council on Scientific Affairs Student Representative, 1990-1993.
RESEARCH
University of Colorado at Denver
Laboratory of Dr. Kathryn Horwitz. Investigation of the mechanism and hormonal regulation of
ovarian cancer metastasis in mouse models.
Duke University Medical Center
Laboratory of Gynecologic Oncology: Investigation of MKK4 regulation in ovarian cancer
with Andrew Berchuck, MD. 2003-2006.
Southeast Gestational Trophoblastic Disease Center: Ten year review of institution experience
with Gestational Trophoblastic Disease, John Soper, MD, 2004-2006.
Brigham and Women’s Hospital
Laboratory of Gynecologic Oncology: Investigation of ETS family oncogenes in ovarian
cancer with Samuel C. Mok, Ph.D. 2000-2003.
Spillman, 10
University of Texas Southwestern
McDermott Center for Human Growth and Development: Investigation of hormone
responsive genes in breast and ovarian cancer, Anne M. Bowcock, Ph.D. 1993-1997.
PEER REVIEW ACTIVITIES
Invited Reviewer, Gynecologic Oncology
Invited Reviewer, Cancer Control, Journal of the Moffitt Cancer Center
GRANT SUPPORT
Current
2009-2011
Ovarian Cancer Research Fund/Liz Tilberis Scholars
“Modulation of Estrogen Response in a Mouse Xenograft Model
of Steroid Hormone Sensitive Ovarian Cancer.”
($150,000/yr/3 yrs)
2008-2009
Avon Foundation
($50,000)
“Banking Normal Tissues from High Risk Breast and Ovarian Cancer Patients.”
2008-2009
Department of Obstetrics and Gynecology, UCHSC
($20,000)
Academic Enrichment Fund
“Banking Normal and Diseased Gynecologic Tissues Removed at Surgery”
Completed
2007-2008
Gynecologic Cancer Foundation
($100,000)
Susan G. Komen Breast Cancer Foundation Career Development Award
“Steroid Hormone Regulation of Extraperitoneal Ovarian Cancer Metastases in Mouse
Models”
2007-2008
Adelson Foundation Ovarian Cancer Research Consortium
($45,000)
2007
Department of Obstetrics and Gynecology, UCHSC
Academic Enrichment Fund
“Mouse Models of Human Ovarian Cancer Distant Metastases”
($10,000)
2003
Ovarian Cancer Research Fund
($75,000)
Program of Excellence Award
“The Role of MAP2K4 in Suppressing Metastasis of Serous Ovarian Cancers”
Submitted
2010
Boettcher Foundation Scholars
“Estrogen Driven Motility Genes in Ovarian Cancer Lymph Node Metastasis”
Spillman, 11